‹ back to 2026-08-04

Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Nature Oncology Therapeutics Toni K. Choueiri, Jaime Merchán, Amita Patnaik, Alexandra Drakaki, Brian I. Rini, Sun Young Rha, Jae Lyun Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Yusra Shao, Se Hoon Park, Pedro C. Barata, Bradley A. McGregor, Paul Foster, Jianfen Chen, Melissa Eisen, Hunter Cole, Ben Weeder, Yinghui Guan, Jaskirat Singh, Angelo Kaplan, Soonweng Cho, Richard Markus, Omar Kabbarah, Rana R. McKay 2026-08-04

TL;DR - This is an Author Correction notice from Nature for a paper reporting that casdatifan, a HIF-2α–targeting agent, produced durable responses in kidney cancer; only the correction title/DOI metadata is available, so no results or data can be summarized. It matters mainly as a provenance/record update to a clinical oncology paper rather than as new AI-advancement material.

Content is thin: the item is metadata only (Nature, published 04 August 2026, doi:10.1038/s41586-026-10958-x), with no abstract, figures, or description of what was corrected.
The underlying subject is HIF-2α biology in renal cell carcinoma — a pathway strongly implicated in VHL-deficient kidney cancer — with casdatifan presented as a therapeutic linked to durable response.
An "Author Correction" typically amends errors in text, figures, author lists, or affiliations without altering the paper's conclusions; that scope cannot be confirmed from the provided content.
No machine learning, model, or computational methodology is mentioned, so this has no direct AI technical takeaway despite arriving from a journal feed.

view merged work →